Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

US biotechs feel the pressure on data exclusivity

This article was originally published in Scrip

Executive Summary

Should biotech firms abandon hope of securing a 12-14-year data exclusivity period in the forthcoming US biosimilars legislation? Certainly things don't seem to be going their way after President Barack Obama came out in favour of a compromise seven-year term, citing the recent Federal Trade Commission report that dismissed the need for anything like 14 years of protection.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC002947

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel